Media Coverage
Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.
CBC Group sets up AffaMed, EverInsight merger, eyes IPO
Complementing Your Psychotherapy
Benzodiazepines Hit With Boxed Warning by FDA
CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate
Michael Liebowitz, MD, VistaGen CNS Clinical and Regulatory Advisory Board Member and Pivotal Phase 3 Principal Investigator: The Mental Health Impact of COVID-19
The Future of Anxiety Treatment Will Be Drastically Different
Pushing Late-Stage Treatments Forward in the Clinic
Treating social anxiety disorder: VistaGen and EverInsight collaborate in Asian markets
VistaGen out-licenses rights to anxiety disorder candidate in Asia territories